Cargando…
Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer
Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell-free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR-103a-3p has been reported in several types of human cancer. However, the role...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669650/ https://www.ncbi.nlm.nih.gov/pubmed/34966454 http://dx.doi.org/10.3892/ol.2021.13156 |
_version_ | 1784614822236651520 |
---|---|
author | Liu, Hui Bian, Qing-Zhao Zhang, Wei Cui, Hai-Bin |
author_facet | Liu, Hui Bian, Qing-Zhao Zhang, Wei Cui, Hai-Bin |
author_sort | Liu, Hui |
collection | PubMed |
description | Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell-free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR-103a-3p has been reported in several types of human cancer. However, the role of miR-103a-3p in BC remains unknown. A total of 112 patients with BC and 59 healthy controls were recruited into the present study. The expression level of serum miR-103a-3p was evaluated using reverse transcription-quantitative PCR. Receiver operating characteristic curves were utilized to calculate diagnostic accuracy. Survival curves were generated to analyze survival outcomes. It was found that circulating miR-103a-3p level was upregulated in patients with BC compared with that in healthy controls, and its expression was decreased following surgery. In addition, miR-103a-3p expression level was also associated with advanced clinicopathological features, including positive epidermal growth factor receptor 2 status, metastasis and an advanced TNM stage. The circulating serum miR-103a-3p level could be used to discriminate between patients with BC and the healthy controls prior to surgery using an area under curve [(AUC), 0.697; 95% confidence intervals (CI), 0.615-0.778], and distinguish patients with BC and metastasis from those without metastasis (AUC, 0.936; 95% CI, 0.892-0.980). In addition, high expression level of miR-103a-3p was associated with worse survival outcomes in patients with BC. In conclusion, the present study suggests that miR-103a-3p could be a potential non-invasive diagnostic and prognostic biomarker for BC. |
format | Online Article Text |
id | pubmed-8669650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-86696502021-12-28 Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer Liu, Hui Bian, Qing-Zhao Zhang, Wei Cui, Hai-Bin Oncol Lett Articles Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell-free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR-103a-3p has been reported in several types of human cancer. However, the role of miR-103a-3p in BC remains unknown. A total of 112 patients with BC and 59 healthy controls were recruited into the present study. The expression level of serum miR-103a-3p was evaluated using reverse transcription-quantitative PCR. Receiver operating characteristic curves were utilized to calculate diagnostic accuracy. Survival curves were generated to analyze survival outcomes. It was found that circulating miR-103a-3p level was upregulated in patients with BC compared with that in healthy controls, and its expression was decreased following surgery. In addition, miR-103a-3p expression level was also associated with advanced clinicopathological features, including positive epidermal growth factor receptor 2 status, metastasis and an advanced TNM stage. The circulating serum miR-103a-3p level could be used to discriminate between patients with BC and the healthy controls prior to surgery using an area under curve [(AUC), 0.697; 95% confidence intervals (CI), 0.615-0.778], and distinguish patients with BC and metastasis from those without metastasis (AUC, 0.936; 95% CI, 0.892-0.980). In addition, high expression level of miR-103a-3p was associated with worse survival outcomes in patients with BC. In conclusion, the present study suggests that miR-103a-3p could be a potential non-invasive diagnostic and prognostic biomarker for BC. D.A. Spandidos 2022-01 2021-12-03 /pmc/articles/PMC8669650/ /pubmed/34966454 http://dx.doi.org/10.3892/ol.2021.13156 Text en Copyright: © Liu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Liu, Hui Bian, Qing-Zhao Zhang, Wei Cui, Hai-Bin Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer |
title | Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer |
title_full | Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer |
title_fullStr | Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer |
title_full_unstemmed | Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer |
title_short | Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer |
title_sort | circulating microrna-103a-3p could be a diagnostic and prognostic biomarker for breast cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669650/ https://www.ncbi.nlm.nih.gov/pubmed/34966454 http://dx.doi.org/10.3892/ol.2021.13156 |
work_keys_str_mv | AT liuhui circulatingmicrorna103a3pcouldbeadiagnosticandprognosticbiomarkerforbreastcancer AT bianqingzhao circulatingmicrorna103a3pcouldbeadiagnosticandprognosticbiomarkerforbreastcancer AT zhangwei circulatingmicrorna103a3pcouldbeadiagnosticandprognosticbiomarkerforbreastcancer AT cuihaibin circulatingmicrorna103a3pcouldbeadiagnosticandprognosticbiomarkerforbreastcancer |